INTRODUCTION

Pulmonary fibrosis (PF) is an incurable and devastating disease represented by destruction and progressive scarring of the lungs with excess connective tissue and extracellular matrix (ECM) deposition. This disease causes respiratory disorder through irreversible loss of the ability to conduct oxygen exchange and eventually leads to death.\textsuperscript{1,2} Idiopathic pulmonary fibrosis (IPF), which is one of the more than 200 types of PF with unknown causes, was initially recognized as an inflammatory disease but was recently considered as being associated with abnormal epithelial cells that activate myofibroblasts and induce ECM remodelling through the secretion of several factors.\textsuperscript{1,3} These secretory molecules include transforming growth factor-beta (TGF-\(\beta\)), connective tissue growth factor (CTGF), tumour necrosis factor, platelet-derived growth factor, osteopontin, angiotensinogen, several matrix metalloproteinases and monocyte chemotactic protein 1, among others.\textsuperscript{1} Therefore, first-line treatments for IPF have shifted from immunosuppressive drugs such as prednisone (a corticosteroid) or azathioprine (an immunosuppressive) to pirfenidone (a pyridinone derivative) or nintedanib (a multi-target tyrosine kinase inhibitor) which...
target these fibrotic growth factors and their receptors, such as TGF-β1, fibroblast growth factor receptors (FGFR) 1-3, platelet-derived growth factor receptor α and β and vascular endothelial growth factor receptors 1-3, and have received approval from the US Food and Drug Administration in 2014 for treating patients with IPF. While these therapies provide a significant milestone in IPF treatment, they show some limitations and slow disease progression but do not stop or cure the disease. Therefore, targeted therapies for IPF based on the cellular and molecular mechanisms of its pathogenesis are needed.

Other TGF-β-signalling target inhibitors such as fresolimumab (GC-1008) and thalidomide are currently being evaluated in clinical trials. TGF-β is a potent pro-fibrotic cytokine for which three isoforms have been identified in mammals: TGF-β1, TGF-β2 and TGF-β3. Among these, TGF-β1 is most closely associated with IPF pathogenesis. During IPF development, secreted TGF-β recruits macrophages and fibroblasts to the wound site and activates fibroblasts. It also provokes the differentiation of fibroblasts to activated myofibroblasts, affecting the production and accumulation of excessive ECM. In contrast, TGF-β1 is also a well-known anti-inflammatory and immunosuppressive factor, and thus approaches aimed at inhibiting TGF-β1 for IPF treatment have been attempted with caution. Recent studies demonstrated that the roles of inflammatory cells are less critical than the therapeutic effect of TGF-β1 signalling inhibition, promoting continuous efforts to develop new TGF-β signalling inhibitors for treating patients with IPF.

In our previous study, we screened chemical libraries using a TGF-β1-responsive luciferase-reported assay system and isolated the imidazopurine compound IM-412 among several candidates. IM-412 suppressed TGF-β-induced fibroblast differentiation via inhibition of both Smad and non-Smad signalling pathways in human normal lung fibroblast. In addition, IM-412 inhibited invasion and migration of MDA-MB-231 breast cancer cells by suppression of epithelial-to-mesenchymal transition (EMT) process. The pharmacological activity of the imidazole moiety has been demonstrated in many medications, including anti-inflammatory, anticancer, antiviral, antitubercular, anticonvulsant and antidepressant activity and imidazo[2,1-f]purine-2,4-dione derivatives exhibited adenosine receptor antagonist and potent activator of serotonin transporter. However, molecular target of imidazopurine compounds and their roles in fibrotic process were not clearly elucidated. Here, we investigated whether another analogue of IM-412, 3-(2-chloro-6-fluorobenzyl)-1,6,7-trimethyl-1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione (IM-1918), inhibits the TGF-β-mediated fibrotic process and also evaluated the underlying mechanisms.

2 | MATERIALS AND METHODS

2.1 | Agents and Antibodies

Primary antibodies against the following molecules were purchased from commercial suppliers: p-Smad2, Smad2, p-Smad3, Smad3, p-p38MAPK, p-Akt, Akt, p-Erk1/2 and p-Src (Cell Signaling Technology); CTGF, fibronectin, pro-collagen, p38MAPK, Erk1/2 and c-Src (Santa Cruz Biotechnology); α-SMA (Sigma); p-FGFR3, FGFR3, p-FGFR1 and FGFR1 (Abcam); β-actin (Sigma-Aldrich); and GAPDH (AbFrontier). Horseradish peroxidase-conjugated secondary antibodies were obtained from Thermo Fisher Scientific. Recombinant human TGF-β1 and FGF-basic were purchased from R&D Systems and Peprotech. IM-1918 (C 17H 15ClFN 5O 2, MW: 376; ID 9082937) was purchased from ChemBridge Corporation. The FGFR inhibitor AZD4547 was obtained from Selleckchem.

2.2 | Cell culture and siRNA transfection

Normal human lung fibroblast CCD18-Lu, IMR90 and WI38 cells and human embryonic kidney HEK2923 cells were purchased from American Type Culture Collection. The cells were maintained at 37°C in minimum essential media or Dulbecco’s modified Eagle medium supplemented with 10% foetal bovine serum (Gibco BRL), 100 U/mL penicillin and 100 μg/mL streptomycin in a 5% CO2 incubator. CCD18-Lu cells were transfected with 10 nmole of scramble RNA or siFGFR3 using Lipofectamine RNAiMAX transfection reagent (Invitrogen) according to the manufacturer’s instructions. After stabilization for 24 hours, the cells were assayed. The following RNA pairs were used: FGFR3, 5′-UGA AAG ACG AUG CCA CUG ACA UU-3′ (forward) and 5′-UGU CAG UGG CAU CGU CUU UCA UU-3′ (reverse).

2.3 | Luciferase reporter assay

For the 3TP-Lux reporter assay, HEK293 cells were transfected with the 3TP-Lux plasmid using Lipofectamine 2000 (Invitrogen). The cells were treated with IM-1918 2 hours prior to adding human recombinant TGF-β1 (1 ng/mL) and incubated for 24 hours. Luciferase activity was assessed using a microplate reader (Wallac Victor, Perkin-Elmer). Relative luciferase activity was normalized against cell viability.

2.4 | Cell viability assessment

Cell viability was determined by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assays (Sigma-Aldrich) or lactate dehydrogenase (LDH) assay. Cells (8 × 10^5) were seeded into 24-well plates (SPL Life Sciences) and stabilized for 24 hours. The indicated dose of IM-1918 was added to each well, and the plate was incubated for 24 hours. MTT (0.5 mg/mL) reagent was added for further incubation for 4 hours, and absorbance was measured at 540-nm using a microplate reader (Multiskan EX, Thermo LabSystems). The release of LDH in culture medium was measured with a commercial assay kit (Dojindo Molecular Technologies, Inc), and absorbance was detected at 490-nm. The experiment was repeated three times. The GI50 value was calculated by GraphPad Prism 5 software (GraphPad, Inc).
2.5 | Western blot analysis

To analyse total proteins, cells or lung tissues were lysed with RIPA buffer (50 mM Tris–Cl, pH 7.4, 1% NP-40, 150 mM NaCl, 1 mM EDTA) supplemented with protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 μg/mL aprotinin and 1 μg/mL leupeptin) and phosphatase inhibitors (1 mM Na3VO4 and 1 mM NaF). Protein samples were separated by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes (Bio-Rad). After blocking non-specific antibody sites, the membranes were probed overnight at 4°C with primary antibodies. The membranes were incubated with peroxidase-conjugated secondary antibodies, and immunoreactive bands were visualized by enhanced chemiluminescence reagents (GE Healthcare). The experiments were repeated at least three times.

2.6 | Bleomycin-induced pulmonary fibrosis mouse model

Six-week-old male C57BL/6 mice were purchased from Dae-Han Laboratory Animal Research Co. (Daejeon, Korea) and housed at 50 ± 10% humidity and 22 ± 2°C with free access to sterile food and water. After acclimatization for 1 week, the mice were randomly distributed into experimental groups (n = 5). The mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg), and then intratracheally administered an instillation of 100 mg/kg bleomycin (BLM; Nippon Kayaku Co.) through a 27-gauge needle. IM-1918 (2 mg/kg) or vehicle (0.1% dimethyl sulfoxide) and water. After acclimatization for 1 week, the mice were randomized distributed into experimental groups (n = 5). The mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg), and then intratracheally administered an instillation of 100 mg/kg bleomycin (BLM; Nippon Kayaku Co.) through a 27-gauge needle. IM-1918 (2 mg/kg) or vehicle (0.1% dimethyl sulfoxide) was intraperitoneally injected every other day, starting on day 1 after BLM treatment. On day 14 after BLM administration, the mice were sacrificed, and the harvested lungs were subjected to immunohistochemical analysis and western blotting. All animal experiments were approved by the Institutional Animal Care and Use Committee of the Korea Institute of Radiological and Medical Sciences.

2.7 | Histological analysis and immunohistochemical staining

The lung tissues were fixed in formalin for 24 hours and embedded in paraffin (Hayashi Pure Chemical Industries). Left lung tissue sections (3 μm) were cut and stained with haematoxylin and eosin or Masson’s trichrome for histopathological examination and evaluation of collagen accumulation. The dewaxed sections were exposed to 3% H2O2 for 10 minutes to block endogenous peroxidase activity, followed by incubation with primary antibody against α-SMA for 60 minutes at room temperature using a Cap-Plus kit (Zymed) according to the manufacturer’s protocol. The sections were then incubated with the biotinylated secondary antibody for 40 minutes, and streptavidin conjugate successively for 30 minutes at room temperature. After three washes (5 minutes each) with PBS-Tween 20, the slides were exposed to diaminobenzidine solution and counterstained with Mayer’s haematoxylin. The sections were mounted in Permount (Thermo Fisher Scientific), and images were obtained using a microscope.

2.8 | Data analysis

Data are represented as means ± SD. Significant differences between groups were determined by analysis of variance and Tukey’s post hoc comparisons using GraphPad software version 5. Statistical significance was defined as P-values < .05.

3 | RESULTS

3.1 | Imidazopurine derivative IM-1918 reduces TGF-β-induced fibrotic process

To develop a novel inhibitor of TGF-β-mediated fibrosis, we previously performed cell-based screening of chemical libraries using a reporter assay of a 3TP-Lux construct stably transfected into HEK293 cells. Among the active candidate compounds, the imidazopurine derivative IM-1918 was identified to be active and inhibit the TGF-β-induced response (Figure 1A,B). IM-1918 dose-dependently inhibited TGF-β-mediated luciferase activity (IC50 = 4.28 μM). To determine whether IM-1918 inhibits TGF-β1-induced cellular responses in lung fibroblast cells, the effect of IM-1918 on cell viability was measured. As shown in Figure 1C, the viability of CCD18-Lu cells was weakly decreased by IM-1918, and the concentration at which 50% inhibition of cell growth occurred (GI50) was 43.58 μM. The GI50 values of IM-1918 for IMR-90 and WI-38 cells could not be determined. TGF-β treatment did not affect cell viability of CCD18-Lu, and the cell viability-induced by IM-1918 was not altered in the presence or absence of TGF-β (Figure S1A,B). In addition, IM-1918 was not shown to be cytotoxic in lung fibroblasts (Figure 1C). Next, the expression of fibrosis-associated TGF-β target molecules was determined. The levels of CTGF, fibronectin, pro-collagen I and α-SMA expression were remarkably increased by TGF-β1 treatment, whereas IM-1918 significantly decreased these proteins in a dose dependent manner (Figure 1D). These data indicate that IM-1918 effectively reduced the TGF-β1-induced fibrotic process without causing cytotoxicity.

3.2 | IM-1918 suppresses non-canonical TGF-β signalling pathways

To investigate the target molecule of IM-1918 in TGF-β1-mediated signalling pathways, we determined the phosphorylation of Smad-2 and Smad-3, a canonical TGF-β signalling pathway. Unlike compound IM-412, which blocked the Smad pathway as we previously described, IM-1918 did not inhibit phosphorylation of either Smad2 or Smad3 (Figure 2A). We next investigated whether IM-1918 could inhibit the Smad-independent signalling pathway, including Akt, extracellular signal-regulated kinase (Erk) 1/2, c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (p38MAPK). IM-1918 inhibited the expression of phosphorylated
Erk1/2 and Akt but did not alter the phosphorylation of JNK or p38MAPK (Figure 2B).

To clarify the inhibitory activity of IM-1918 towards target proteins, an in vitro kinase assay was performed (Table 1). Interestingly, most kinases tested showed no significant inhibition by IM-1918, and only seven kinases were slightly inhibited by approximately 10%. Additionally, IM-1918 did not directly inhibit Erk1/2, Akt or TGF-β receptor (TGFBR1, TGFBR2). IM-1918 showed the highest inhibitory activity towards FGFR3 with 36.09% inhibition, followed by FGFR1 with 18.36% inhibition. Because FGFR3 is structurally similar to FGFR1, particularly at the ATP binding site, the levels of FGFR1/3 and phosphorylated FGFR1/3 were determined. The levels of FGFR3 expression were not altered by IM-1918, while the phosphorylation level of FGFR3 was decreased by IM-1918 treatment. IM-1918 also effectively inhibited the phosphorylation of FGFR1 without altering FGFR1 protein expression (Figure 2C). These results demonstrate that IM-1918 reserved TGF-β-induced Smad signalling cascades, but decreased the expression of fibrosis-related genes by inhibiting non-classical Smad signalling pathways through partial suppression of the receptor tyrosine kinase activity of FGFR1/3.

3.3 IM-1918 inhibits basic fibroblast growth factor (bFGF)-mediated fibrotic process

Because FGF signalling has been implicated in the pathogenesis of PF and co-operatively cross-talks with TGF-β1,20 we investigated whether IM-1918 disrupts the bFGF-induced fibrotic process. Treatment with bFGF increased the activation of FGFR1/3.
**FIGURE 2** IM-1918 inhibits TGF-β-induced fibrotic response via Erk1/2 and AKT down-regulation. CCD18-Lu cells were treated with the indicated dose of IM-1918. Two hours later, TGF-β1 (1 ng/mL) was added, and the cells were incubated for 24 h. Total protein was isolated and analysed by Western blotting for the indicated proteins. A, Smad signalling. B, Non-Smad signalling. C, FGFR

**TABLE 1** Activity of IM1918 in an in vitro kinase assay

| Kinase          | Activity (average, %) | Kinase          | Activity (average, %) |
|-----------------|-----------------------|-----------------|-----------------------|
| FGFR3           | 63.91 ± 0.185         | ERK2/MAPK1      | 99.5 ± 0.695          |
| FGFR1           | 81.64 ± 2.185         | ALK             | 99.71 ± 0.556         |
| p70S6K/RPS6KB1  | 85.35 ± 0.056         | GRK2            | 100.33 ± 1.444        |
| FYN             | 85.89 ± 1.698         | ROS/RO51        | 100.54 ± 2.611        |
| P38a/MAPK14     | 87.79 ± 7.829         | JAK3            | 100.84 ± 0.61         |
| YES/YES1        | 88.15 ± 1.999         | JNK3/MAPK10     | 100.89 ± 2.331        |
| ZAP70           | 89.47 ± 2.099         | AKT2            | 101.83 ± 3.632        |
| AKT1            | 90.26 ± 1.076         | FAK/PTK2        | 101.86 ± 0.26         |
| JAK1            | 91.38 ± 0.141         | TAK1/MAPK7      | 101.95 ± 8.525        |
| IGF1R           | 92.08 ± 1.335         | ASK1/MAPK3K     | 102.25 ± 0.841        |
| IKKb/IKBK       | 92.18 ± 2.026         | JNK1/MAPK8      | 102.42 ± 2.462        |
| PKA             | 93.6 ± 1.914          | ERK1/MAPK3      | 102.6 ± 3.873         |
| PAK2            | 95.07 ± 1.978         | SRC/c-Src       | 102.66 ± 2.875        |
| SYK             | 95.6 ± 3.765          | PYK2/PTK2B      | 102.69 ± 0.918        |
| ROCK1           | 95.77 ± 1.82          | TYK2            | 102.83 ± 12.29        |
| JNK2/MAPK9      | 96.35 ± 2.736         | PDK1/PDPK1      | 105.71 ± 2.438        |
| FGFR2           | 96.77 ± 1.601         | TYK1/LTK        | 106.77 ± 3.737        |
| TYRO3/SKY       | 96.94 ± 0.975         | PAK1            | 107.06 ± 5.566        |
| JAK2            | 96.97 ± 8.383         | RAF1            | 107.28 ± 8.001        |
| BRAF            | 97.74 ± 1.883         | IRAK4           | 109.78 ± 1.391        |
| P38b/MAPK11     | 98.61 ± 2.143         | ARAF            | 119.05 ± 1.864        |
| TGFBR1/ALK5     | 98.88 ± 0.483         | TGFBR2          | 134.3 ± 2.88          |
| GSK3b           | 99.19 ± 5.12          |                 |                       |
and phosphorylation of Akt and Erk1/2 (Figure 3A). In agreement with the above results, IM-1918 did not directly alter the expression level of fibrosis-related molecules but attenuated the induction of FGFR1/3, Erk1/2 and Akt following bFGF treatment. Interestingly, the phosphorylation of Smad-2 and Smad-3 was increased by bFGF, while these proteins were not suppressed by IM-1918 treatment. Additionally, we evaluated the effect of IM-1918 on Src, which is the best-characterized non-receptor tyrosine kinase. Src can interact with receptor tyrosine kinases (RTKs) and activate downstream signalling molecules such as Erk1/2 and Akt.21-23 Moreover, targeting of Src is considered effective for attenuating fibrosis.24 As expected, phosphorylation of Src was markedly increased by bFGF, whereas IM-1918 suppressed this induction.

The bFGF treatment of CCD18-Lu cells induced about 20% more proliferation than control cells whereas IM-1918 inhibited bFGF-induced cell proliferation to the control levels (Figure S1C,D). Treatment with bFGF also enhanced the expression level of fibrotic proteins, including fibronectin, pro-collagens I, CTGF and α-SMA (Figure 3B). These up-regulated proteins were significantly decreased by treatment with IM-1918, indicating that IM-1918 attenuated the bFGF-mediated fibrotic process by suppressing FGFR1/3.

### 3.4 Inhibition of FGFR3 disrupts TGF-β1-mediated fibrotic process

To verify that inhibition of FGFR3 blocks TGF-β1-induced fibrotic activity, pharmacologic inhibition of FGFR3 using AZD4547 treatment or knockdown of FGFR3 by short interfering RNA genetic inactivation was performed. AZD4547, a well-known pan-FGFR inhibitor, slightly suppressed the phosphorylation of FGFR3 at the doses tested in this study. Moreover, AZD4547 did not alter fibrotic protein expression, except for decreasing phosphorylated Erk1/2. Similar to the results shown in Figure 2, TGF-β1 increased downstream signalling molecules, whereas this enhanced expression of fibrotic markers and related signalling proteins were markedly decreased by AZD4547 (Figure 4A,C).

Treatment with siFGFR3 inhibited the levels of FGFR and phosphorylated FGFR3 expression, while FGFR1 proteins were not changed. Additionally, only phosphorylated Akt was decreased by siFGFR3. Nevertheless, siFGFR3 effectively suppressed TGF-β1-induced fibrotic activity, which was similar to the results of AZD4547 treatment (Figure 4B,D). These results indicate that pharmacological and genetic inhibition of FGFR3 can suppress the TGF-β1-mediated fibrotic process. These results indicate that inhibition of FGFR3 under normal conditions (without TGF-β1 or bFGF stimuli) can be
easily and rapidly compensated by one of the other subtypes of FGFR or by redundant downstream signalling molecules.

3.5 | IM-1918 attenuates BLM-induced murine pulmonary fibrosis

To investigate the efficacy of IM-1918 on fibrosis in animals, a murine BLM-induced lung fibrosis model was used. Immunohistochemical analysis revealed that BLM-induced accumulation of collagen, and α-SMA was markedly inhibited by IM-1918 (Figure 5A). Furthermore, several signalling molecules and fibrotic markers investigated by in vitro analysis were significantly increased in the lung tissues of BLM-treated mice (Figure 5B,C). In accordance with the above results, increased expression of proteins involved in the BLM-induced fibrotic process was markedly attenuated by administration of IM-1918. These results demonstrate that IM-1918 can inhibit PF both in vivo and in vitro. Based on these findings, the molecular mechanisms of the anti-fibrotic effect of IM-1918 are schematically illustrated in Figure 6.

4 | DISCUSSION

TGF-β is a major causative factor of symptoms of fibrotic diseases and multifunctional cytokine that plays various roles in the body. In this study, the novel compound IM-1918 effectively suppressed the expression of fibrosis-related molecules up-regulated by TGF-β1 in a Smad-independent manner. Although we identified IM-1918 in a TGF-β1-responsive reporter assay, the putative primary target of IM-1918 is FGFR3 based on data from an in vitro kinase assay. Most kinases, including TGFBR1, TGFBRII, EGFR, AKT, p38MAPK, ERK1/2, JNK, RAF and JAK, among others, were not affected by IM-1918.

Several studies have demonstrated that administration of TGF-β1 changes the sensitivities of FGFRs and activates the production
of FGF-2 in primary human lung fibroblasts.\textsuperscript{25-27} FGFs are associated with the pathogenesis of PF, and FGF2-neutralizing antibodies successfully inhibit the TGF-β1-mediated fibrotic process.\textsuperscript{20} It has been also reported that FGF-2 and FGFR1IIIc are involved in EMT and advanced cancer progression, which may be regulated by TGF-β1 autonomously secreted from cancer cells.\textsuperscript{25,28} Moreover, non-selective inhibition of RTKs and non-specific inhibition of FGFRs decrease BLM-induced PF in rodents.\textsuperscript{7,29} Altered expression of FGFR1 and FGF1 proteins was observed in the lungs of patients with IPF,\textsuperscript{30} and a specific FGFR1 inhibitor (NP603) attenuated carbon tetrachloride-induced hepatic fibrosis in rats.\textsuperscript{31} In addition to FGF, epidermal growth factor, which acts through RTKs, can synergize with TGF-β1 signalling to increase collagen accumulation and interstitial fibrosis,\textsuperscript{32,33} suggesting that a co-operative network exists between RTKs and TGF-β1. In agreement with these observations, administration of TGF-β1 to CCD18-Lu fibroblasts increased the phosphorylation of FGFR3 and FGFR1, accompanied by induction of ECM proteins in this study. Although all FGFR1-4 were expressed in freshly isolated lung mesenchyme, only FGFR1 was expressed when isolated fibroblasts are cultured.\textsuperscript{20} In addition, low expression levels of FGFR3 and FGFR4 in cultured lung fibroblasts was also reported.\textsuperscript{34} Therefore, we cautiously propose that although the inhibitory activity of IM-1918 on FGFR3 was about two-fold higher than on FGFR1, FGFR1 expression in lung fibroblasts was much higher than that of FGFR3, allowing clear exhibition of FGFR1 inhibition. Nevertheless, the redundancy of FGFs/
FGFRs allows reciprocal compensation of the deficiency of each and crosstalk with TGF-β1 signalling utilizes the same and similar downstream effectors, such as Src and Erk activation to maintain their biological functions. In this regard, it is worth that IM-1918 effectively inhibited the TGF-β1 or bFGF-induced fibrotic process by suppression of Src/Akt as well as ECM accumulation. However, the exact types of FGFs/FGFRs and isoforms of FGFRs, which are critical targets for FGFs/FGFRs, interactions of related receptors, and cellular mechanisms involved in fibrosis remain unclear. This is because these factors are highly dependent on the cells or experiments used and the degree of differentiation, and further studies are continually required to identify individual roles of each FGFRs in vitro and in vivo.

FGFRs and Smad independent signaling. FGFRs also allows reciprocal compensation of the deficiency of each and crosstalk with TGF-β1 signalling utilizes the same and similar downstream effectors, such as Src and Erk activation to maintain their biological functions. In this regard, it is worth that IM-1918 effectively inhibited the TGF-β1 or bFGF-induced fibrotic process via suppression of Src/Akt as well as ECM accumulation. However, the exact types of FGFs/FGFRs and isoforms of FGFRs, which are critical targets for FGFs/FGFRs, interactions of related receptors, and cellular mechanisms involved in fibrosis remain unclear. This is because these factors are highly dependent on the cells or experiments used and the degree of differentiation, and further studies are continually required to identify individual roles of each FGFRs and specific intermediate signals in pulmonary fibrosis. In contrast, although BLM-induced PF does not perfectly resemble the pathology and chronicity of human PF, BLM remains a well-established and useful model for studying PF. In vivo, BLM administration significantly decreased CTGF, fibronectin, α-SMA and collagen accumulation in a BLM-induced lung fibrosis animal model, suggesting that IM-1918 is a highly efficacious anti-fibrotic agent with potential for further clinical application.

Recently, an important study showed that the relative amounts of FGF-2 and TGF-β determine the invasive potential by FGFR substrate (FRS2) regulation in medulloblastoma. Upon ligand (FGF) binding to FGFR, dimerization causes the receptors to rapidly auto-transphosphorylate several tyrosine residues, leading to activation of downstream molecules, such as FRS2 and phospholipase C-gamma. Activated FRS2 triggers the Ras/MAPK kinase signaling pathway. FRS2 also has been shown to recruit Src, which regulates numerous signaling cascades involved in cell viability, proliferation, differentiation, migration and metabolism. We revealed that IM-1918 decreased PI3K/Akt and Erk1/2 activity in non-classical TGF-β1 pathways. Additionally, clear inhibition of TGF-β1-induced fibroblast differentiation was demonstrated when the cells were exposed to IM-1918, the pan-FGFR inhibitor AZD4547 and siFRG3. These effects of IM-1918 involve concurrent disruption of TGF-β1- and FGFR3-mediated signalling pathways converged on the Src/Akt/Erk axis.

In summary, we demonstrated that the interplay between TGF-β1 and FGFR3 may promote fibrotic disease in human lung fibroblasts. Additionally, the new small molecule IM-1918 significantly inhibits the TGF-β1-mediated fibrotic process by suppressing the FGFR3-Src/Akt/Erk signalling pathway. Although abundant feedback and parallel signalling pathways can limit the efficacy of this compound or the value of the targets, such as FGFs, FGFRs and Src, additional studies are needed to develop a successful strategy for treating patients with PF.

**ACKNOWLEDGEMENT**

This work was supported by grants from the Korea Institute of Radiological and Medical Sciences, funded by Ministry of Science and ICT, Republic of Korea (50531-2017; 50538-2019).

**CONFLICT OF INTEREST**

The authors declare that they have no competing interests.

**AUTHOR CONTRIBUTIONS**

M-H Kim, S-Y Jung, K-H Song and J-I Park performed the research. M-H Kim performed the animal experiment. M-H Kim, S-Y Jung, H-J Woo and J-Y Song designed the research study. M-H Kim, S-Y Jung, K-H Song and J-Y Song analysed the data. J. Ahn, E-H Kim, JK Park, S-G Hwang and H-J Woo participated in discussion. M-H Kim, S-Y Jung and J-Y Song wrote the paper.

**ORCID**

Jie-Young Song https://orcid.org/0000-0002-5769-3886

**DATA AVAILABILITY STATEMENT**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

**REFERENCES**

1. Martinez FJ, Collard HR, Pardo A, et al. Idiopathic pulmonary fibrosis. *Nat Rev Dis Primers*. 2017;3:17074.
2. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med*. 2006;174:810-816.
3. Fujimoto H, Kobayashi T, Azuma A. Idiopathic pulmonary fibrosis: treatment and prognosis. Clin Med Insights Circ Respir Pulm Med. 2015;9:179-185.

4. Card JW, Racz WJ, Brien JF, Margolín SB, Massey TE. Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity. Toxicol Sci. 2003;75:169-180.

5. Conte E, Gili E, Fagone E, Fruciano M, Lemmolo M, Vancheri C. Effect of pirfenidone on proliferation, TGF-beta-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci. 2014;58:13-19.

6. Macias-Barragan J, Sandoval-Rodriguez A, Navarro-Partida J, Armendáriz-Borunda J. The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair. 2010;3:16.

7. Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. Antiinflammatory and anti-inflammatory activity of the tyrosine kinase inhibitor nilTedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther. 2014;349:209-220.

8. Karimi-Shah BA, Chowdhury BA. Forced vital capacity in idiopathic pulmonary fibrosis–FDA review of pirfenidone and nintedanib. N Engl J Med. 2015;372:1189-1191.

9. Shimbori C, Bellaye PS, Xia J, et al. Fibroblast growth factor-1 attenuates TGF-beta1-induced lung fibrosis. J Pathol. 2016;240:197-210.

10. Rafi R, Juarez MM, Albertson TE, Chan AL. A review of current and novel therapies for idiopathic pulmonary fibrosis. J Thorac Dis. 2013;5:48-73.

11. Fernandez IE, Eickelberg O. The impact of TGF-beta on lung fibrosis: from targeting to biomarkers. Proc Am Thorac Soc. 2012;9:111-116.

12. Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-beta: the master regulator of fibrosis. Nat Rev Nephrol. 2016;12:325-338.

13. Park S, Ahn JY, Lim MJ, et al. IM-412 inhibits transforming growth factor-beta-induced fibroblast differentiation in human lung fibroblast cells. Biochem Biophys Res Commun. 2010;399:268-273.

14. Jung SY, Yi JY, Kim MH, et al. IM-412 inhibits transforming growth factor-beta-induced fibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci. 2010;39:34-151.

15. Shalmali N, Ali MR, Bawa S. Imidazole: an essential edifice for the identification of new lead compounds and drug development. Mini Rev Med Chem. 2018;18:142-163.

16. Drabczynska A, Karcz T, Szymanska E, et al. Synthesis, biological activity and molecular modelling studies of tricyclic alkylamidazo-, pyrimido- and diazepinoneindiones. Purinergic Signal. 2013;9:345-414.

17. Zagorska A, Czopek A, Pawlowski M, Dybala M, Siwek A, Nowak G. Serotonin transporter activity of imidazolidine-2,4-dione and imidazol[2,1-f]urine-2,4-dione derivatives in aspect of their acid-base stability and the cell permeability of 2-pyrimidinyl-piperazinyl-alkyl derivatives of 1H-imidazol[2,1-f]urine-2,4(3H,8H)-dione with antidepressant- and anxiolytic-like activities. Chem Biol Drug Des. 2019;93:511-521.

18. Zagorska A, Partyka A, Bucki A, et al. Characteristics of metabolic stability and the cell permeability of 2-pyrimidinyl-piperazinyl-alkyl derivatives of 1H-imidazol[2,1-f]urine-2,4(3H,8H)-dione with antidepressant- and anxiolytic-like activities. Chem Biol Drug Des. 2019;93:511-521.

19. Lazar MH, Christensen PJ, Du M, et al. Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin. Am J Respir Cell Mol Biol. 2004;31:672-678.

20. Guzy RD, Li L, Smith C, et al. Pulmonary fibrosis requires cell-autonomous mesenchymal fibroblast growth factor (FGF) signaling. J Biol Chem. 2017;292:10364-10378.

21. Guarino M. Src signaling in cancer invasion. J Cell Physiol. 2010;223:14-26.

22. Ren M, Qin H, Ren R, Tidwell J, Cowell JK. Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases. Cancer Res. 2011;71:7312-7322.

23. Sandilands E, Akbarzadeh S, Vecchione A, McEwan DG, Frame MC, Heath JK. Src kinase modulates the activation, transport and signalling dynamics of fibroblast growth factor receptors. EMBO Rep. 2007;8:1162-1169.

24. Wang J, Wang L, Xu L, et al. Targeting Src attenuates peritoneal fibrosis and inhibits the epithelial to mesenchymal transition. Oncotarget. 2017;8:83872-83889.

25. Shirakihara T, Horiguchi K, Miyazawa K, et al. TGF-beta regulates isoform switching of FGF receptors and epithelial-mesenchymal transition. EMBO J. 2011;30:783-795.

26. Finlay GA, Thanickal VJ, Fanburg BL, Paulson KE. Transforming growth factor-beta 1-induced activation of the ERK pathway/activator protein-1 in human lung fibroblasts requires the autocrine induction of basic fibroblast growth factor. J Biol Chem. 2000;275:27650-27656.

27. Khalil N, Xu YD, O’Connor R, Duronio V. Proliferation of pulmonary interstitial fibroblasts is mediated by transforming growth factor-beta1-induced release of extracellular fibroblast growth factor-2 and phosphorylation of p38 MAPK and JNK. J Biol Chem. 2005;280:43000-43009.

28. Acevedo VD, Gangula RD, Freeman KW, et al. Inducible FGFR1-activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell. 2007;12:559-571.

29. Yu ZH, Wang DD, Zhou ZY, He SL, Chen AA, Wang J. Mutant soluble ectodomain of fibroblast growth factor receptor-2 IIc attenuates bleomycin-induced pulmonary fibrosis in mice. Biol Pharm Bull. 2012;35:731-736.

30. MacKenzie B, Korfei M, Henneke I, et al. Increased FGFR1-FGFRc expression in idiopathic pulmonary fibrosis. Respir Res. 2015;16:83.

31. Lin N, Chen S, Pan W, Xu L, Hu K, Xu R. NP603, a novel and potent inhibitor of FGFR1 tyrosine kinase, inhibits hepatic stellate cell proliferation and ameliorates hepatic fibrosis in rats. Am J Physiol Cell Physiol. 2011;301:C469-474.

32. Katsumo Y, Lamouille S, Derynck R. TGF-beta signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol. 2013;25:76-84.

33. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009;19:156-172.

34. Srisuma S, Bhattacharya S, Simon DM, et al. Fibroblast growth factor receptors control epithelial-mesenchymal interactions necessary for alveolar elongogenesis. Am J Respir Crit Care Med. 2010;181:838-850.

35. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40:362-382.

36. Mouraris MA, Aidinis V. Modeling pulmonary fibrosis with bleomycin. Curr Opin Pulm Med. 2011;17:355-361.

37. Santhana Kumar K, Neve A, Guerreiro Stucklin AS, et al. TGF-beta determines the pro-migratory potential of bFGF signaling in medulloblastoma. Cell Rep. 2018;23:3798-3812 e8.

38. Mohammadi M, Honegger AM, Rotin D, et al. A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1. Mol Cell Biol. 1991;11:5068-5078.

39. Gotoh N. Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins. Cancer Sci. 2008;99:1319-1325.

40. Kouchara H, Hadari YR, Spivak-Kroizman T, et al. A lipid-anchored Grib2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell. 1997;89:693-702.

41. Choi SC, Kim SJ, Choi JH, Park CY, Shim WJ, Lim DS. Fibroblast growth factor-2 and -4 promote the proliferation of bone marrow mesenchymal stem cells by the activation of the PI3K-Akt and ERK1/2 signaling pathways. Stem Cells Dev. 2008;17:725-736.

42. Frame MC. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta. 2002;1602:114-130.

43. Parsons SJ, Parsons JT. Src family kinases, key regulators of signal transduction. Oncogene. 2004;23:7906-7909.
44. Ingley E. Src family kinases: regulation of their activities, levels and identification of new pathways. Biochim Biophys Acta. 2008;1784:56-65.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Kim M-H, Jung S-Y, Song K-H, et al. A new FGFR inhibitor disrupts the TGF-β1-induced fibrotic process. J Cell Mol Med. 2020;24:830–840. https://doi.org/10.1111/jcmm.14793